Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety.
Title
Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety.
Identifier
/unibl/sci/idNaucniRad:7053
Type
See all items with this valueConference Paper
Date
Bibliographic Citation
S. Jungić, G. Kecman Malčić, I. Rakita, D. Jovanović, R. Gajanin, Z. Marić, T. Biljana, Z. Gojković, Bevacizumab in combination with irinotecan and capecitabine as first line treatment for MCRC efficacy and safety., Annals of Oncology 2014; 25 (Supplement 2):, pp. 68 - 68, Jun, 2014
page start
68
page end
68
presented at
ESMO 16th World Congress on Gastrointestinal Cancer
Is Part Of
See all items with this valueAnnals of Oncology 2014; 25 (Supplement 2):
list of authors
Position: 24243 (31 views)